BML discloses 8.3% Oramed Pharmaceuticals (ORMP) ownership in 13G/A

Rhea-AI Filing Summary

BML Investment Partners, L.P. and Braden M. Leonard filed an amended Schedule 13G disclosing a significant stake in Oramed Pharmaceuticals Inc. Leonard reports beneficial ownership of 3,287,531 shares of common stock, representing 8.3% of the class, including 120,300 shares over which he has sole voting and dispositive power and 3,167,231 shares with shared power.

The filing states these securities are not held for the purpose of changing or influencing control of Oramed, and the reporting persons disclaim that they form a statutory group.

Insights

Equity ownership and governance analyst

Oramed gains a passive 8.3% shareholder with shared and sole voting powers.

BML Investment Partners, L.P. and Braden M. Leonard report beneficial ownership of 3,287,531 Oramed common shares, or 8.3% of the class. Leonard has sole voting and dispositive power over 120,300 shares and shared power over 3,167,231 shares.

The certification indicates the position is not intended to change or influence control of Oramed, aligning it with a passive investment stance. The disclaimer that the parties do not form a statutory group under Rule 13d-5(b)(1) also limits inferences about coordinated control activity from this ownership level.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ORAMED PHARMACEUTICALS INC.

(Name of Issuer)

Common Stock par value $0.012 per share

(Title of Class of Securities)

68403P203

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68403P203

1

Names of Reporting Persons

BML Investment Partners, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,167,231.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,167,231.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,167,231.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 68403P203

1

Names of Reporting Persons

Leonard Braden Michael

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 120,300.00
6	Shared Voting Power 3,167,231.00
7	Sole Dispositive Power 120,300.00
8	Shared Dispositive Power 3,167,231.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,287,531.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Securities Exchange Act of 1934

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ORAMED PHARMACEUTICALS INC.
(b)	Address of issuer's principal executive offices: 1185 Avenue of the Americas, Third Floo, New York, New York, 10036
Item 2.
(a)	Name of person filing: BML Investment Partners, L.P
(b)	Address or principal business office or, if none, residence: 65 E Cedar, Suite 2 Zionsville, IN 46077
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock par value $0.012 per share
(e)	CUSIP No.: 68403P203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3287531
(b)	Percent of class: 8.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 120300
	(ii) Shared power to vote or to direct the vote: 3167231
	(iii) Sole power to dispose or to direct the disposition of: 120300
	(iv) Shared power to dispose or to direct the disposition of: 3167231
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BML Investment Partners, L.P.

Signature:	Braden M Leonard
Name/Title:	BML Capital Management, LLC its General Partner By: Braden M Leonard, its Managing Member
Date:	02/09/2026

Leonard Braden Michael

Signature:	Braden M Leonard
Name/Title:	Leonard Braden Michael
Date:	02/09/2026

Comments accompanying signature: BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.

FAQ

What stake in Oramed Pharmaceuticals (ORMP) does BML Investment Partners and Braden M. Leonard report?

BML Investment Partners and Braden M. Leonard report beneficial ownership of 3,287,531 Oramed shares, or 8.3% of the common stock. This includes 120,300 shares over which Leonard has sole voting and dispositive power, plus 3,167,231 shares with shared voting and dispositive power.

How many Oramed (ORMP) shares does BML Investment Partners, L.P. beneficially own?

BML Investment Partners, L.P. reports beneficial ownership of 3,167,231 Oramed common shares, representing 7.9% of the class. For these shares, the partnership has shared voting and shared dispositive power, with no sole voting or sole dispositive authority reported in the Schedule 13G/A amendment.

What voting and dispositive powers does Braden M. Leonard have over Oramed (ORMP) shares?

Braden M. Leonard has sole voting and dispositive power over 120,300 Oramed shares and shared power over 3,167,231 shares. In total, this results in beneficial ownership of 3,287,531 shares, or 8.3% of Oramed’s outstanding common stock, according to the amended Schedule 13G.

Is the BML and Braden M. Leonard stake in Oramed (ORMP) filed as a passive investment?

Yes. The certification states the Oramed securities were not acquired or held to change or influence control of the issuer. The filing characterizes the position as passive under Schedule 13G and specifies it is not connected with transactions intended to influence control, aside from certain nomination activities.

Do BML Investment Partners and Braden M. Leonard report themselves as a statutory group in Oramed (ORMP)?

No. The reporting persons expressly disclaim that they constitute a statutory group under Rule 13d-5(b)(1). While Leonard is deemed an indirect owner of shares held by BML Investment Partners, they state this shared beneficial ownership does not form a formal group for Exchange Act purposes.

What is the key date associated with this Oramed (ORMP) Schedule 13G/A filing?

The Schedule 13G/A identifies December 31, 2025 as the date of the event requiring the filing. Signatures from Braden M. Leonard on behalf of BML Capital Management, LLC and in his individual capacity are dated February 9, 2026, confirming the ownership information as of that reporting timeframe.